[go: up one dir, main page]

UA81625C2 - Применение ротиготина для трансепикутального лечения синдрома уставших ног - Google Patents

Применение ротиготина для трансепикутального лечения синдрома уставших ног

Info

Publication number
UA81625C2
UA81625C2 UA20041109078A UA20041109078A UA81625C2 UA 81625 C2 UA81625 C2 UA 81625C2 UA 20041109078 A UA20041109078 A UA 20041109078A UA 20041109078 A UA20041109078 A UA 20041109078A UA 81625 C2 UA81625 C2 UA 81625C2
Authority
UA
Ukraine
Prior art keywords
restless leg
leg syndrome
rotigotin
epicutaneous
trans
Prior art date
Application number
UA20041109078A
Other languages
English (en)
Ukrainian (uk)
Inventor
Томас Лаутербах
Эрвин Шоллмайер
Original Assignee
Шварц Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29285132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA81625(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шварц Фарма Аг filed Critical Шварц Фарма Аг
Publication of UA81625C2 publication Critical patent/UA81625C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Это изобретение относится к трансэпикутальной фармацевтической композиции, которая содержит ротиготин (Rotigotin), для лечения синдрома уставших ног (RLS), особенно в форме трансдермальной терапевтической системы (TDS) на основе акрилата или силикона, которые имеют поверхность 2,5-20 см, и содержит 1,125 -9,0 мг/смротиготина как активного компонента против синдрома уставших ног, который вызывает улучшение состояния пациентов - людей с синдромом уставших ног – по сравнению с лечением плацебо на 2 единицы или более согласно шкале оценок Международной группы исследования синдрома уставших ног (IRLSSG) после введения на протяжении периода времени, по меньшей мере, 8 суток.
UA20041109078A 2002-05-06 2003-05-05 Применение ротиготина для трансепикутального лечения синдрома уставших ног UA81625C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10220230A DE10220230A1 (de) 2002-05-06 2002-05-06 Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
PCT/EP2003/004685 WO2003092677A1 (de) 2002-05-06 2003-05-05 Transepikutane darreichungsform zur behandlung des restless leg syndroms

Publications (1)

Publication Number Publication Date
UA81625C2 true UA81625C2 (ru) 2008-01-25

Family

ID=29285132

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041109078A UA81625C2 (ru) 2002-05-06 2003-05-05 Применение ротиготина для трансепикутального лечения синдрома уставших ног

Country Status (23)

Country Link
EP (1) EP1501499B1 (ru)
JP (2) JP5253707B2 (ru)
KR (1) KR20040104697A (ru)
CN (1) CN100396281C (ru)
AT (1) ATE387912T1 (ru)
AU (1) AU2003233233B2 (ru)
BR (1) BR0309837A (ru)
CA (2) CA2483120C (ru)
CY (1) CY1107452T1 (ru)
DE (2) DE10220230A1 (ru)
DK (1) DK1501499T3 (ru)
ES (1) ES2301795T3 (ru)
IL (2) IL164861A0 (ru)
MX (1) MXPA04010687A (ru)
NO (1) NO333619B1 (ru)
NZ (1) NZ536533A (ru)
PL (1) PL218549B1 (ru)
PT (1) PT1501499E (ru)
RU (1) RU2301063C9 (ru)
SI (1) SI1501499T1 (ru)
UA (1) UA81625C2 (ru)
WO (1) WO2003092677A1 (ru)
ZA (1) ZA200408862B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
RU2428179C2 (ru) 2006-05-08 2011-09-10 Тейкоку Сейяку Ко., Лтд. Препаративные формы лекарственных средств против слабоумия для чрескожного введения
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
AU2008328920B2 (en) 2007-11-28 2013-09-12 Ucb Pharma Gmbh Polymorphic form of Rotigotine
WO2009107477A1 (ja) 2008-02-27 2009-09-03 久光製薬株式会社 貼付製剤
US9155725B2 (en) 2008-02-27 2015-10-13 Hisamitsu Pharmaceutical Co., Inc. Adhesive skin patch and packaged product
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
PT3257504T (pt) 2009-12-22 2024-09-03 Ucb Biopharma Sprl Polivinilpirrolidona para a estabilização de uma dispersão sólida da forma não cristalina de rotigotina
US8729306B2 (en) 2010-02-05 2014-05-20 Ucb Pharma Gmbh Process for the preparation of nitrogen substituted aminotetralins derivatives
JP5748848B2 (ja) 2010-06-25 2015-07-15 ウーツェーベー ファルマ ゲーエムベーハーＵｃｂ Ｐｈａｒｍａ Ｇｍｂｈ 窒素置換（ｓ）−５−アルコキシ−２−アミノテトラリン誘導体の分割方法
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
WO2013075823A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
EP2870962B1 (en) * 2012-07-05 2018-09-12 SK Chemicals Co., Ltd. Transdermally absorbable preparation containing rotigotine
JP2015522013A (ja) * 2012-07-06 2015-08-03 エスケー ケミカルス カンパニー リミテッド ロチゴチン含有経皮吸収製剤
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
US10045948B2 (en) 2014-02-27 2018-08-14 Medrx Co., Ltd. Pramipexole-containing transdermal patch for treatment of neurodegenerative disease
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
JP6599899B2 (ja) 2014-05-20 2019-10-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 界面介在物を含む経皮送達システム
ES2924899T3 (es) 2014-05-20 2022-10-11 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que contiene rotigotina
WO2020250840A1 (ja) 2019-06-14 2020-12-17 久光製薬株式会社 ロチゴチン含有貼付剤
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5232702A (en) * 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
DE4238223C1 (de) * 1992-11-12 1994-05-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung
US5482988A (en) * 1994-01-14 1996-01-09 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive with siloxylated polyether waxes as additives
IL116539A (en) * 1995-01-06 2002-02-10 Noven Pharma Preparations given through the skin of unstable anti-acid drugs
FR2749514B1 (fr) * 1996-06-11 1998-08-07 Hoechst Marion Roussel Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19938825A1 (de) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
PT1256339E (pt) * 2001-05-08 2004-02-27 Lohmann Therapie Syst Lts Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina
DK1256340T3 (da) * 2001-05-08 2003-12-01 Sanol Arznei Schwarz Gmbh Forbedret transdermalt, terapeutisk system til behandlingen af Parkinsons sygdom

Also Published As

Publication number Publication date
IL164861A (en) 2011-06-30
CN1665497A (zh) 2005-09-07
NZ536533A (en) 2010-02-26
JP2010159302A (ja) 2010-07-22
JP5253707B2 (ja) 2013-07-31
CA2483120A1 (en) 2003-11-13
AU2003233233A1 (en) 2003-11-17
AU2003233233B2 (en) 2008-03-06
HK1072541A1 (zh) 2005-09-02
EP1501499A1 (de) 2005-02-02
CN100396281C (zh) 2008-06-25
PT1501499E (pt) 2008-05-20
DK1501499T3 (da) 2008-06-23
NO333619B1 (no) 2013-07-22
SI1501499T1 (sl) 2008-06-30
CA2787384A1 (en) 2003-11-13
PL373276A1 (en) 2005-08-22
MXPA04010687A (es) 2005-06-08
JP2005528413A (ja) 2005-09-22
DE10220230A1 (de) 2003-11-27
WO2003092677A1 (de) 2003-11-13
ES2301795T3 (es) 2008-07-01
NO20045240L (no) 2004-11-30
BR0309837A (pt) 2005-03-01
CY1107452T1 (el) 2012-12-19
PL218549B1 (pl) 2014-12-31
ZA200408862B (en) 2005-09-28
EP1501499B1 (de) 2008-03-05
RU2004131866A (ru) 2005-06-10
CA2483120C (en) 2013-07-16
IL164861A0 (en) 2005-12-18
RU2301063C9 (ru) 2007-11-27
ATE387912T1 (de) 2008-03-15
KR20040104697A (ko) 2004-12-10
DE50309318D1 (de) 2008-04-17
RU2301063C2 (ru) 2007-06-20

Similar Documents

Publication Publication Date Title
UA81625C2 (ru) Применение ротиготина для трансепикутального лечения синдрома уставших ног
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
AU2003301190A1 (en) Administration of capsaicinoids
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
BRPI0414481A (pt) métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
RU2003133217A (ru) Чрескожная терапевтическая система для лечения болезни паркинсона, индуцирующая высокие уровни ротиготина в плазме
EP1261340A4 (en) COMPOSITIONS AND METHODS FOR TREATING PARKINSON DISEASE
ATE400258T1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
DE50114474D1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
WO2004010946A3 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
MXPA02003484A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
TW200719903A (en) Compositions for the treatment of neoplasms
WO2005056520A8 (en) Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy
SE0102887D0 (sv) New formulation
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
WO2019035646A8 (ko) 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica